WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Chinese Scientists Develop New Method to Preserve Female FertilityInPics: New Year Fair Adds Happiness on Guizhou's 'Slow Trains'More Chinese Mainland Universities Enter World's Top 100 ListChina Surges to StraightChina Adds 158 New Professions to Occupation ListFarmers Embrace Apple Harvest in Southwest ChinaBeijing Sets up Fever Clinics in All Community Health Service CentersTraditional Chinese Cultural Activities Attract Tourists During National Day HolidayChinese Dream Inspires Nation on Journey AheadBeijing Sets up Fever Clinics in All Community Health Service Centers
3.0467s , 6501.6484375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Informer news portal